Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Filings indexed 678 across all filing types
Latest filing 2026-06-02 Share Issue/Capital Cha…
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Updates
Share Issue/Capital Change Classification · 94% confidence The document is an official stock exchange filing under SEBI Listing Obligations disclosing the allotment of equity shares upon exercise of employee stock options, including details of share numbers, exercise price, ISIN, etc. This is a direct announcement of new share issuance and a change in share capital, fitting the “Share Issue/Capital Change” category (Code: SHA).
2026-06-02 English
Allotment of 2,03,259 Equity Shares on exercise of Employee Stock Options
Share Issue/Capital Change Classification · 95% confidence The document is an exchange filing (to BSE & NSE) notifying the allotment of equity shares on exercise of employee stock options, detailing the increase in issued share capital and share issuance specifics under SEBI regulations. This constitutes an announcement of a new share issue/capital change. Therefore, it falls under Share Issue/Capital Change (SHA).
2026-06-02 English
Schedule of Investor Meet
Regulatory Filings Classification · 85% confidence The document is an intimation to stock exchanges under SEBI Listing Regulations informing the schedule of analyst and institutional investor meetings. It is a regulatory announcement/disclosure rather than a substantive financial report, earnings release, or proxy material. Hence it falls into the general Regulatory Filings category (RNS).
2026-05-29 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 82% confidence The document is a formal intimation to stock exchanges under SEBI Listing Regulations, providing the schedule of upcoming analyst/institutional investor meetings. It does not contain financial statements, earnings data, or AGM materials, nor is it a proxy, dividend, or capital change announcement. It is a general regulatory announcement, which falls under the fallback “Regulatory Filings” category (RNS).
2026-05-29 English
Schedule of Investor Meet
Regulatory Filings Classification · 88% confidence The document is a compliance disclosure under SEBI LODR Regulation 30 notifying stock exchanges of the schedule for analyst/institutional investor meetings. It does not contain financial results, presentations, or voting results, nor is it a report itself. It is a general regulatory announcement that fits the fallback category for miscellaneous filings. Therefore, it is classified as Regulatory Filings (RNS).
2026-05-26 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 88% confidence The document is a regulatory announcement addressed to stock exchanges providing the schedule of analyst/institutional investor meetings pursuant to listing disclosure requirements. It is not a financial report, earnings release, or management presentation, nor is it soliciting votes or detailing corporate actions. It is a general compliance/regulatory disclosure, fitting the “Regulatory Filings (RNS)” fallback category.
2026-05-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.